Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

The Word Brain 2015Free PDF | Print | Web
A short guide to fast language learning

Free Abstracts

  Alzheimer's Disease

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 51 articles:
HTML format
Text format



Single Articles


    June 2015
  1. TANZI RE
    TREM2 and Risk of Alzheimer's Disease - Friend or Foe?
    N Engl J Med. 2015;372:2564-5.
    PubMed     Text format     Abstract available


  2. MITCHELL SL
    CLINICAL PRACTICE. Advanced Dementia.
    N Engl J Med. 2015;372:2533-40.
    PubMed     Text format    


    April 2014
  3. DE LA TORRE JC
    Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
    N Engl J Med. 2014;370:1459-60.
    PubMed     Text format    


  4. LASKE C
    Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
    N Engl J Med. 2014;370:1459.
    PubMed     Text format    


  5. DOODY RS, Farlow M, Aisen PS
    Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
    N Engl J Med. 2014;370:1460.
    PubMed     Text format    


  6. SALLOWAY S, Sperling R, Brashear HR
    Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
    N Engl J Med. 2014;370:1460.
    PubMed     Text format    


    February 2014
  7. WUNDERINK RG, Waterer GW
    Clinical practice. Community-acquired pneumonia.
    N Engl J Med. 2014;370:543-51.
    PubMed     Text format    


    January 2014
  8. KARRAN E, Hardy J
    Antiamyloid therapy for Alzheimer's disease - are we on the right road?
    N Engl J Med. 2014;370:377-8.
    PubMed     Text format     Abstract available


  9. SALLOWAY S, Sperling R, Fox NC, Blennow K, et al
    Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease.
    N Engl J Med. 2014;370:322-33.
    PubMed     Text format     Abstract available


  10. DOODY RS, Thomas RG, Farlow M, Iwatsubo T, et al
    Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
    N Engl J Med. 2014;370:311-21.
    PubMed     Text format     Abstract available


    October 2013
  11. POMARA N
    Semagacestat for treatment of Alzheimer's disease.
    N Engl J Med. 2013;369:1661.
    PubMed     Text format    


  12. GUPTA VB , Gupta VK, Martins R
    Semagacestat for treatment of Alzheimer's disease.
    N Engl J Med. 2013;369:1660-1.
    PubMed     Text format    


  13. DOODY RS , Aisen PS, Iwatsubo T
    Semagacestat for treatment of Alzheimer's disease.
    N Engl J Med. 2013;369:1661.
    PubMed     Text format    


  14. GUERREIRO R , Hardy J
    TREM2 and neurodegenerative disease.
    N Engl J Med. 2013;369:1569-70.
    PubMed     Text format    


  15. BIRD TD
    TREM2 and neurodegenerative disease.
    N Engl J Med. 2013;369:1568.
    PubMed     Text format    


  16. BENITEZ BA , Cruchaga C
    TREM2 and neurodegenerative disease.
    N Engl J Med. 2013;369:1567-8.
    PubMed     Text format    


  17. RAJAGOPALAN P , Hibar DP, Thompson PM
    TREM2 and neurodegenerative disease.
    N Engl J Med. 2013;369:1565-7.
    PubMed     Text format    


  18. BERTRAM L , Parrado AR, Tanzi RE
    TREM2 and neurodegenerative disease.
    N Engl J Med. 2013;369:1565.
    PubMed     Text format    


  19. REITZ C , Mayeux R
    TREM2 and neurodegenerative disease.
    N Engl J Med. 2013;369:1564-5.
    PubMed     Text format    


  20. JONSSON T , Stefansson K
    TREM2 and neurodegenerative disease.
    N Engl J Med. 2013;369:1568-9.
    PubMed     Text format    


    July 2013
  21. DOODY RS , Raman R, Farlow M, Iwatsubo T, et al
    A phase 3 trial of semagacestat for treatment of Alzheimer's disease.
    N Engl J Med. 2013;369:341-50.
    PubMed     Text format     Abstract available


  22. LIGHT DW , Darrow J
    Regulation of drugs for early Alzheimer's disease.
    N Engl J Med. 2013;369:288.
    PubMed     Text format    


  23. KOZAUER N , Katz R
    Regulation of drugs for early Alzheimer's disease.
    N Engl J Med. 2013;369:288.
    PubMed     Text format    


    March 2013
  24. KOZAUER N , Katz R
    Regulatory Innovation and Drug Development for Early-Stage Alzheimer's Disease.
    N Engl J Med. 2013.
    PubMed     Text format     Abstract available


    February 2013
  25. GRIFFIN WS
    Neuroinflammatory cytokine signaling and Alzheimer's disease.
    N Engl J Med. 2013;368:770-1.
    PubMed     Text format    


    January 2013
  26. WILLIS MS , Patterson C
    Proteotoxicity and cardiac dysfunction--Alzheimer's disease of the heart?
    N Engl J Med. 2013;368:455-64.
    PubMed     Text format    


  27. LING SM , Bonner AF, McMullen TL
    Discontinuation of risperidone in Alzheimer's disease.
    N Engl J Med. 2013;368:187.
    PubMed     Text format    


  28. POWER GA
    Discontinuation of risperidone in Alzheimer's disease.
    N Engl J Med. 2013;368:186-7.
    PubMed     Text format    


  29. GNJIDIC D , Hilmer SN
    Discontinuation of risperidone in Alzheimer's disease.
    N Engl J Med. 2013;368:186.
    PubMed     Text format    


  30. DEVANAND DP , Schultz SK, Sultzer DL
    Discontinuation of risperidone in Alzheimer's disease.
    N Engl J Med. 2013;368:187-8.
    PubMed     Text format    


    December 2012

  31. Relapse risk after discontinuation of risperidone in Alzheimer's disease.
    N Engl J Med. 2012;367:2458.
    PubMed     Text format     Abstract available


    November 2012
  32. LASKE C
    Clinical and biomarker changes in Alzheimer's disease.
    N Engl J Med. 2012;367:2050.
    PubMed     Text format    


  33. PIMPLIKAR SW
    Clinical and biomarker changes in Alzheimer's disease.
    N Engl J Med. 2012;367:2050-1.
    PubMed     Text format    


  34. FLOREZ JC
    Clinical and biomarker changes in Alzheimer's disease.
    N Engl J Med. 2012;367:2051.
    PubMed     Text format    


  35. NEUMANN H , Daly MJ
    Variant TREM2 as Risk Factor for Alzheimer's Disease.
    N Engl J Med. 2012.
    PubMed     Text format     Abstract available


  36. GUERREIRO R , Wojtas A, Bras J, Carrasquillo M, et al
    TREM2 Variants in Alzheimer's Disease.
    N Engl J Med. 2012.
    PubMed     Text format     Abstract available


  37. JONSSON T , Stefansson H, Ph D SS, Jonsdottir I, et al
    Variant of TREM2 Associated with the Risk of Alzheimer's Disease.
    N Engl J Med. 2012.
    PubMed     Text format     Abstract available


    October 2012
  38. DEVANAND DP , Mintzer J, Schultz SK, Andrews HF, et al
    Relapse risk after discontinuation of risperidone in Alzheimer's disease.
    N Engl J Med. 2012;367:1497-507.
    PubMed     Text format     Abstract available


    September 2012
  39. YANG L , Rieves D, Ganley C
    Brain amyloid imaging--FDA approval of florbetapir F18 injection.
    N Engl J Med. 2012;367:885-7.
    PubMed     Text format    


    August 2012
  40. GANDY S
    Lifelong management of amyloid-beta metabolism to prevent Alzheimer's disease.
    N Engl J Med. 2012;367:864-6.
    PubMed     Text format    


  41. LAFERLA FM
    Preclinical success against Alzheimer's disease with an old drug.
    N Engl J Med. 2012;367:570-2.
    PubMed     Text format    


  42. LOWENTHAL J , Hull SC, Pearson SD
    The ethics of early evidence--preparing for a possible breakthrough in Alzheimer's disease.
    N Engl J Med. 2012;367:488-90.
    PubMed     Text format    


    July 2012
  43. BATEMAN RJ , Xiong C, Benzinger TL, Fagan AM, et al
    Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease.
    N Engl J Med. 2012.
    PubMed     Text format     Abstract available


    June 2012
  44. FINUCANE MM , Finucane TE
    Discontinuing donepezil or starting memantine for Alzheimer's disease.
    N Engl J Med. 2012;366:2227-8.
    PubMed     Text format    


  45. SUZUKI T
    Discontinuing donepezil or starting memantine for Alzheimer's disease.
    N Engl J Med. 2012;366:2227-8.
    PubMed     Text format    


    March 2012
  46. SCHNEIDER LS
    Discontinuing donepezil or starting memantine for Alzheimer's disease.
    N Engl J Med. 2012;366:957-9.
    PubMed     Text format    


  47. HOWARD R , McShane R, Lindesay J, Ritchie C, et al
    Donepezil and memantine for moderate-to-severe Alzheimer's disease.
    N Engl J Med. 2012;366:893-903.
    PubMed     Text format     Abstract available


    February 2012
  48. VAIDYA A , Dolan BM, Edlow BL, Rinne ML, et al
    Interactive medical case. A startling decline.
    N Engl J Med. 2012;366:e11.
    PubMed     Text format    


    January 2012
  49. MAJOUNIE E , Abramzon Y, Renton AE, Perry R, et al
    Repeat Expansion in C9ORF72 in Alzheimer's Disease.
    N Engl J Med. 2012.
    PubMed     Text format     Abstract available


    December 2011
  50. ARTENSTEIN AW , Opal SM
    Proprotein convertases in health and disease.
    N Engl J Med. 2011;365:2507-18.
    PubMed     Text format    


    September 2011
  51. OKIE S
    Confronting Alzheimer's disease.
    N Engl J Med. 2011;365:1069-72.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


All AMEDEO services are free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Amedeo is a Flying Publisher website.

   Design: